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fractions for 5 days a week. Toxicity was recorded using the 
CTCAE v4.0 to define a Dose Limiting Toxicity (DLT) and a 
Maximum Tolerated Dose (MTD) of MTL005. 
 
Results: A total of 8 patients, 7 males (88%) and 1 female 
(12%), were enrolled, 4 in each of the 2 dose level cohorts. 
Six patients, all male with median age of 65 (54-77), were 
dosed with MTL005 successfully, 3 in each cohort. Dosing 
failures were due to an unexpected severe pain reaction (1 
patient) and a technical problem with the infusion line (1 
patient). In the 6 evaluable patients the following adverse 
events were recorded. Grade ≤2 oral mucositis and dysphagia 
were recorded in 3 (50%) and 4 (67%) patients respectively. 
Grade 1 pain in site of MTL005 injection was assessed in 1 
(17%) patient. Grade ≤2 other toxicities (anaemia, dysgeusia) 
occurred in 3 (50%) patients. Grade 3 (dyspnoea, 
pneumonitis, oral haemorrhage, back pain, hyperuricemia) 
and Grade 4 toxicity (sepsis) were recorded in 4 (67%) and 1 
(17%) cases respectively requiring hospitalisation and being 
considered as Serious Adverse Events (SAE). None of the SAE 
was assessed as directly related to MTL005 so DLT/MTD was 
not defined. 
 
Conclusion: We completed Part 1 of the study and MTL005 
DLT/MTD was not defined. Part 2 has been commenced with 
a MTL005 starting dose of 4mg/kg and is currently ongoing. 
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Purpose or Objective: To assess the prognostic role of 18F -
FDG PET/CT based response evaluation after primary 
concomitant radio-chemotherapy (RCT) for loco regionally 
advanced Head and Neck squamous cell carcinoma (HNSCC). 
 
Material and Methods: 150 patients were included in this 
retrospective study. Mean age was 59 years (107 males and 
43 females). The sites of HNSCC were oropharynx (53%), 
nasopharynx (14%), oral cavity (10%), hypopharynx (7%), 
larynx (7%), salivary glands (5%) and paranasal sinuses (4%). 
All patients underwent 18F-FDG PET/CT between 2006 and 
2013 to assess treatment response; 62% of patients also had a 
pre-therapy 18F -FDG PET/CT scan. 18F -FDG PET/CT was 
performed from 6 to 36 weeks (median 21 weeks) after the 
end of RCT. Patients were divided in three groups: 18F -FDG 
PET/CT performed from 6 to 14 weeks after the end of RCT 
(group I: 30 patients), from 15 to 23 weeks (group II: 89 
patients) and from 24 to 36 weeks (group III: 31 patients). 
18F -FDG PET/CT scans were performed according to 
standard procedure, then they were visually analysed by 2 
expert physicians and categorized as negative (“score 1”), 
doubt negative (“score 2”), doubt positive (“score 3”) and 
positive (“score 4”). Patients were followed-up, based on 
clinic and radiological and/or histological findings. Median 
follow up was 38 months (range, 12-60 months). At the end 
of the follow-up 18F-FDG PET/CT were classified as true 
positive (TP), true negative (TN), false positive (FP) and false 
negative (FN). 
 
Results: Group I showed “score 1” in 14 patients, “score 4” 
in 11 patients and therefore 18F-FDG PET/CT sensitivity was 
69%, specificity 83%, VPP 82%, VPN 72%, and accuracy 0.76. 
This group showed 5 doubt scans (16%) as “score 2” that were 
find out to be 2 negatives and 3 positives. No “score 3” was 
observed in this group. Group II showed “score 1” in 55 
patients, “score 4” in 27 patients and therefore 18F-FDG 
PET/CT sensitivity was 87%, specificity 98%, VPP 96%, VPN 
93%, and accuracy 0.94. This group showed 7 (8%) doubt 
scans: 3 scans (3.5%) as “score 2” that in follow-up were 1 
negative and 2 positives and 4 scans (4.5%) as “score 3” that 
were found out to be 2 negatives and 2 positives. Group III 
showed “score 1” in 24 patients and “score 4” in 6 patients 
and therefore 18F-FDG PET/CT sensitivity was 86%, 
specificity 100%, VPP 100%, VPN 96%, and accuracy 0.97. This 
group showed only 1 doubt scan (3%) as “score 2” that was 
find out to be negative. 
 
Conclusion: According to our data, PET/CT with 18F-FDG 
showed an excellent prognostic value of treatment response 
to primary concomitant RCT if performed at least 14 weeks 
after the end of RCT. We also observed that the numbers of 
“doubt scans” significantly decrease 14 weeks after the end 
of RCT. 
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Purpose or Objective: The role of post-operative external 
beam radiotherapy (EBRT) in differentiated thyroid 
carcinomas is still discussed considering the low clinical 
aggressiveness and the possibility to perform a radioiodine 
ablation (RAI). However, there are dedifferentiated tumors 
that, over time, lose their capacity to capture Iodine. The 
aim of this study is to evaluate the utility of 18F-FDG PET/CT 
in volumes defining and the clinical response rate after EBRT 
in these patients. 
 
Material and Methods: Patients with locally recurrent thyroid 
cancer, treated with radical EBRT from October 2011 to 
March 2015 after total thyroidectomy and RAI, were included 
in the study. When EBRT was planned, thyroglobulin (HTG) 
was detectable and there was negative post-RAI whole body 
scintigraphy (WBS) and no surgical indications. All patients 
underwent a pre-treatment 18F-FDG PET/CT that resulted 
positive: 3 in loggia, 3 in loggia and lymph nodes, 9 in lymph 
nodes, 1 in lymph nodes and in lung. EBRT was delivered with 
IMRT-SIB technique: a dose of 66 Gy (2.2 Gy/fr) to increased 
FDG-uptake areas, 60 Gy (2 Gy/fr) to ipsilateral lymph nodes 
and 54 Gy (1.8 Gy/fr) to contralateral ones, in 30 fractions, 1 
fr/die. A revaluation 18F-FDG PET/CT and HTG dosage during 
the follow-up (range: 5-43 months) was performed. Acute 
and late toxicity were assessed with CTCAE v. 4.03 and 
EORTC-RTOG scales respectively, the metabolic, clinical and 
instrumental response with PERCIST and RECIST criteria. 
Local control (LC) and overall survival (OS) were analysed 
with Kaplan-Meier method. 
 
Results: Sixteen patients were treated and analyzed 
consecutively [M / F: 8/8; median age: 71 years; range: 36-
81; histology: 15 papillary carcinomas and 1 follicular 
carcinoma; UICC stage: III-IV]. Post-EBRT 18F-FDG PET/CT 
showed CR in 7 (43.8%), PR in 5 (31.2%), SD in 4 (25.0%) 
patients and unknown lung metastases in 2 patients (12.5%). 
HTG decreased in agreement with PET/CT results. 4 patients 
(25.0%) had G3 skin acute toxicity and no one showed G4 late 
toxicity. LC and OS rates were 100% at last follow-up (median 
F-UP: 12.3 months). 
 
